CAR-T
“A Revolutionary Breakthrough in Cancer Treatment”
CAR-T cell therapy is one of the most advanced immunotherapies in our product pipeline, recognized by both government authorities and international experts. Using advanced gene-editing and cell culture technologies, we modify and expand patient T cells into highly active and specific CAR-T cell products, several of which have successfully advanced into clinical stages.
Product Overview
CAR-T therapy is an autologous treatment in which a synthetic CAR gene is introduced into a patient’s own T cells through genetic engineering. These modified T cells are able to specifically recognize tumor-associated antigens, become activated, and efficiently kill cancer cells.
The CAR structure includes a single-chain variable fragment for antigen recognition, a transmembrane domain, and intracellular activation domains. Once the CAR-T cells bind to tumor antigens, the intracellular activation domain initiates signal transduction to activate T cells, and release perforin and granzymes to induce tumor cell apoptosis. CAR-T cells also secrete cytokines that recruit other immune cells, enhancing the overall anti-tumor immune response.
Precision Targeting: CAR-T cells selectively bind to tumor-specific antigens, minimizing damage to healthy cells.
Potent Anti-Tumor activity: Engineered T cells exhibit robust proliferation and long-lasting activity, sustaining tumor clearance.
Personalized Therapy: Autologous manufacturing ensures individualized treatment adapted to each patient’s tumor antigen characteristics.
Advantages
Clinical Applications
Hematologic Malignancies: CAR-T therapy is widely applied in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma (NHL).
Relapsed or Refractory Patients: Demonstrates remarkable efficacy, with some patients achieving long-term remission or even cure.
Solid Tumors: Ongoing research is expanding CAR-T applications into breast, lung, liver, gastric and colorectal cancers, where our projects are showing encouraging potential in clinical trials.
CAR-T combined with PD-1 knockout for non-small cell lung cancer: conducted in collaboration with the First Affiliated Hospital of Guangzhou Medical University and the University of Technology Sydney; registered on ClinicalTrials.gov (NCT03525782).
CAR-T combined with PD-1 knockout for esophageal cancer:
Conducted with the same collaborators; registered on ClinicalTrials.gov (NCT03706326).
PD-1 knockout and MUC1-targeted CAR-T (AJMUC10 for advanced MUC1-positive breast cancer:
In collaboration with Sun Yat-sen Memorial Hospital, Sun Yat-sen University; registered on the China Clinical Trial Registry (ChiCTR1900025088)